Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein.
about
Modes of paramyxovirus fusion: a Henipavirus perspectiveMeasles Virus Fusion Protein: Structure, Function and InhibitionHenipavirus mediated membrane fusion, virus entry and targeted therapeuticsBinding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion proteinA general strategy to endow natural fusion-protein-derived peptides with potent antiviral activityPotent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.Hendra and Nipah viruses: different and dangerous.Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitroViral entry inhibitors targeted to the membrane site of action.Off Label Antiviral Therapeutics for Henipaviruses: New Light Through Old Windows.A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatmentA functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system.Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.Inhibition of hendra virus fusion.Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screeningFeline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine.Hendra and nipah infection: pathology, models and potential therapies.Emerging paramyxoviruses: molecular mechanisms and antiviral strategiesSpring-loaded heptad repeat residues regulate the expression and activation of paramyxovirus fusion protein.Molecular determinants of antiviral potency of paramyxovirus entry inhibitors.Developments towards effective treatments for Nipah and Hendra virus infection.A novel receptor-induced activation site in the Nipah virus attachment glycoprotein (G) involved in triggering the fusion glycoprotein (F)Targeted strategies for henipavirus therapeuticsRecent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.Cholesterol-conjugated peptide antivirals: a path to a rapid response to emerging viral diseases.Henipavirus pathogenesis and antiviral approaches.A quantitative and kinetic fusion protein-triggering assay can discern distinct steps in the nipah virus membrane fusion cascadeMutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization.N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry.Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin.Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins.Pathobiology of henipavirus entry: insights into therapeutic strategies
P2860
Q24604089-FA89E57A-37BD-4045-AAD7-5AF3AC718716Q26750552-F7C13457-013C-4ACB-9B57-B22B2C3A3590Q27002511-5A3E805F-2D52-4882-839D-A59358C831FEQ27658463-0572057A-3862-458A-86EF-96A9D51213CAQ28729918-8F46F8E7-55EA-46D0-ACCF-35E2C7031321Q30805028-C8773EF9-1FC5-4B89-951D-C1FFA27C2E73Q31026413-09E7D18C-304D-4FC9-A14E-5C3C5D971958Q33514948-1298546C-5430-4815-A912-B6A0AC968FD0Q33990602-4BEC95AB-1680-4C97-9D24-D84B30975D0CQ34021811-841E2254-DF3B-4066-9E88-59BDE444FE0EQ34120677-893CE380-6FDA-4F27-BCE2-9C3C4D125D26Q34365035-7F371218-DAD9-4C47-9434-2588D5952179Q34545923-61F4E27D-DFAF-47BB-97B5-0C845F8E0F1CQ35101317-06F0D518-25E8-41E5-BCD3-C7CC31E34CB3Q35134796-25B5CC2C-2A78-4021-AC9F-3F895B56F938Q35185973-801EF663-EF91-420B-B732-C57521269B65Q35658146-01A84B0B-E459-4531-8D82-7F5CBF73A423Q35658152-13FEC9CD-4BE0-46CB-8513-2131FEA56BB6Q35785110-3D39D7AC-DBBF-4E76-93C6-448F0BDDCE47Q36099124-D1F69C58-7B79-4CBF-BCBB-E34408F791C8Q36379335-6F6DF1A5-7F1C-4157-B152-50812F140FA8Q37041588-2A6C89C8-E181-48CE-BF5A-7B8FD157E38FQ37175177-093BDB87-4673-46A7-B5B7-947BEBDE539AQ37412509-A8A0B425-B8A7-41D5-8C51-F028A50D57F9Q38261556-0C31B6E0-16A3-4C77-B9FF-6488528A0823Q38337204-FD108548-ADE5-4E65-810E-B1AEECD5EB6FQ39697289-30B4A4B7-E42A-47F7-A01D-BA69DA9D75E7Q40226883-000D3BC0-E68E-43C4-9088-E6E5E6B538BCQ40287207-E3497F93-1D06-476D-A637-15C84941C1E0Q41041346-716C4929-0F0C-4626-988E-053BDE5FD245Q41579136-999694A6-4FCA-4EA4-A7E0-391BB6FC09B9Q56912178-2C389B70-F17F-44FA-996D-12074A27481C
P2860
Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Inhibition of Henipavirus fusi ...... ipah virus fusion glycoprotein
@nl
Inhibition of Henipavirus fusi ...... pah virus fusion glycoprotein.
@ast
Inhibition of Henipavirus fusi ...... pah virus fusion glycoprotein.
@en
type
label
Inhibition of Henipavirus fusi ...... ipah virus fusion glycoprotein
@nl
Inhibition of Henipavirus fusi ...... pah virus fusion glycoprotein.
@ast
Inhibition of Henipavirus fusi ...... pah virus fusion glycoprotein.
@en
altLabel
Inhibition of Henipavirus fusi ...... ipah virus fusion glycoprotein
@en
prefLabel
Inhibition of Henipavirus fusi ...... ipah virus fusion glycoprotein
@nl
Inhibition of Henipavirus fusi ...... pah virus fusion glycoprotein.
@ast
Inhibition of Henipavirus fusi ...... pah virus fusion glycoprotein.
@en
P2093
P2860
P50
P3181
P356
P1433
P1476
Inhibition of Henipavirus fusi ...... pah virus fusion glycoprotein.
@en
P2093
Bryan T Eaton
Christopher C Broder
Gary Crameri
P2860
P2888
P3181
P356
10.1186/1743-422X-2-57
P407
P577
2005-07-18T00:00:00Z
P6179
1044431490